The arrival of a 750mcg teriparatide injection in Australia has generated considerable discussion within the healthcare community. Currently, its availability is limited, primarily through specialist endocrinologists and qualified centers. Distribution figures for this concentrated form remain somewhat difficult to ascertain, but indications sugges